Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020 06 01; 138(6):698-701.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Angiogenesis Inhibitors
Bevacizumab
Bevacizumab
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Female
Female
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Infant
Infant
Infant, Newborn
Infant, Newborn
Intravitreal Injections
Intravitreal Injections
Male
Male
Receptors, Vascular Endothelial Growth Factor
Receptors, Vascular Endothelial Growth Factor
Retina
Retina
Retinopathy of Prematurity
Retinopathy of Prematurity
Treatment Outcome
Treatment Outcome
authors with profiles
Raymond M Siatkowski